TrialBlood2016

Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.

Christine E Ryan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.